Greg Pyszczymuka - Mar 31, 2025 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role
Chief Commercial Officer
Signature
/s/ Ryan Selhorn as attorney-in-fact for Greg Pyszczymuka
Stock symbol
AYTU
Transactions as of
Mar 31, 2025
Transactions value $
$0
Form type
4
Date filed
3/31/2025, 04:34 PM
Previous filing
Feb 24, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AYTU Common Shares Options Exercise +209 +0.89% 23.6K Mar 31, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AYTU Restricted Stock Units Options Exercise $0 -209 -100% $0.00 0 Mar 31, 2025 Common Shares 209 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.